GSK (ticker: GSK) adds treasury shares through late‑May 2026 buyback activity

Rhea-AI Filing Summary

GSK plc reports that, under its existing share buyback programme, it repurchased ordinary shares of 31¼ pence each on 26–29 May 2026 through Citigroup Global Markets Limited. Daily purchases ranged from 301,200 to 319,949 shares, at volume weighted average prices between 1,899.95 and 1,932.82 GBp per share.

The repurchased shares will be held as treasury shares. Since 11 May 2026 the company has bought 4,590,420 ordinary shares. After these transactions, GSK holds 265,968,706 ordinary shares in treasury and has 4,050,256,108 ordinary shares in issue, which is also the total number of voting rights, with 6.57 per cent of voting rights attributable to treasury shares.

Key Figures

26 May 2026 shares bought: 301,200 shares 29 May 2026 VWAP: 1,899.95 GBp/share Shares bought since 11 May 2026: 4,590,420 shares +4 more

7 metrics

26 May 2026 shares bought 301,200 shares Ordinary shares repurchased on 26 May 2026

29 May 2026 VWAP 1,899.95 GBp/share Volume weighted average price on 29 May 2026

Shares bought since 11 May 2026 4,590,420 shares Total ordinary shares repurchased since 11 May 2026

Treasury share balance 265,968,706 shares Ordinary shares held in treasury after purchases

Shares in issue 4,050,256,108 shares Ordinary shares in issue excluding treasury shares

Voting rights in issue 4,050,256,108 Total number of voting rights after purchases

Treasury voting rights percentage 6.57 per cent Voting rights attributable to treasury shares under DTR 5.5.1R

Key Terms

treasury shares, buyback programme, Disclosure Guidance and Transparency Rules, Market Abuse Regulation (EU) No 596/2014, +1 more

5 terms

treasury shares financial

"The purchased shares will be held as Treasury shares."

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

buyback programme financial

"Such share purchases form part of the Company's existing buyback programme"

Disclosure Guidance and Transparency Rules regulatory

"under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules."

Disclosure guidance and transparency rules are the standards and regulations that require companies to share clear, timely information about their finances, risks, operations and material events. They matter to investors because consistent, honest reporting is like a car’s dashboard — it reveals the data you need to judge safety and performance and make informed buying or selling decisions. Strong disclosure reduces surprises and helps keep markets fair and efficient.

Market Abuse Regulation (EU) No 596/2014 regulatory

"In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014"

voting rights financial

"the total number of voting rights in the Company will be 4,050,256,108."

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Transaction in own shares

GSK plc (the "Company") announces today acting through Citigroup Global Markets Limited (the "Broker"), it has purchased the following number of the Company's ordinary shares of 31¼ pence each.

Date of purchase	Aggregate number of ordinary shares of 31 ¼ pence each purchased	Lowest price paid per share (GBp)	Highest price paid per share (GBp)	Volume weighted average price paid per share (GBp)
26 May 2026	301,200	1,900.00	1,942.50	1,922.09
27 May 2026	319,674	1,909.50	1,942.00	1,932.82
28 May 2026	307,448	1,906.00	1,935.50	1,921.76
29 May 2026	319,949	1,885.50	1,918.50	1,899.95

The purchased shares will be held as Treasury shares.

Such share purchases form part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 8 May 2026, as announced on 11 May 2026.  Since 11 May 2026 the Company has purchased 4,590,420 ordinary shares.

Following the above purchases, the Company will hold 265,968,706 ordinary shares in treasury and have 4,050,256,108 ordinary shares in issue (excluding Treasury shares).

Following the above purchases, the total number of voting rights in the Company will be 4,050,256,108. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above purchases the percentage of voting rights attributable to the ordinary shares held in treasury is 6.57 per cent.

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended, a full breakdown of the individual purchases of ordinary shares made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) is set out in the Schedule to this announcement, available via the link below:

http://www.rns-pdf.londonstockexchange.com/rns/4657G_1-2026-6-1.pdf

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

GSK enquiries
Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Sam Piper	+44 (0) 7824 525779	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q1 Results for 2026.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: June 01, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What share buybacks did GSK (GSK) complete in late May 2026?

GSK repurchased ordinary shares of 31¼ pence each on 26–29 May 2026, buying between 301,200 and 319,949 shares per day at volume weighted average prices from 1,899.95 to 1,932.82 GBp, as part of its existing share buyback programme.

How many GSK (GSK) shares has the company repurchased since 11 May 2026?

Since 11 May 2026, GSK has repurchased 4,590,420 ordinary shares. These purchases form part of the company’s existing buyback programme and are being executed under a non-discretionary agreement with Citigroup Global Markets Limited, as previously announced on 11 May 2026.

How many GSK (GSK) shares are now held in treasury and in issue?

Following the late May 2026 buybacks, GSK holds 265,968,706 ordinary shares in treasury and has 4,050,256,108 ordinary shares in issue, excluding treasury shares. The 4,050,256,108 ordinary shares in issue also represent the total number of voting rights in the company.

What percentage of GSK (GSK) voting rights are held in treasury shares?

GSK confirms that 6.57 per cent of its voting rights are attributable to ordinary shares held in treasury. This percentage is calculated in line with DTR 5.5.1R and reflects the company’s treasury position following the latest share repurchases announced in this report.

How can GSK (GSK) shareholders use the updated voting rights figure?

Shareholders can use the updated total of 4,050,256,108 voting rights as the denominator when assessing whether they must notify holdings or changes in holdings under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules following GSK’s recent share buybacks.